Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H45NO3.ClH |
| Molecular Weight | 468.112 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12CC[C@@]3([H])[C@@]([H])(CN4C[C@@H](C)CC[C@@]4([H])[C@@]3(C)O)[C@]1([H])C[C@@]5([H])[C@@]2([H])C[C@H](O)[C@@]6([H])C[C@@H](O)CC[C@]56C
InChI
InChIKey=RDNDJVJNDWTGGV-LOGDSNHLSA-N
InChI=1S/C27H45NO3.ClH/c1-15-4-7-25-27(3,31)21-6-5-17-18(20(21)14-28(25)13-15)11-22-19(17)12-24(30)23-10-16(29)8-9-26(22,23)2;/h15-25,29-31H,4-14H2,1-3H3;1H/t15-,16-,17+,18+,19-,20-,21-,22-,23+,24-,25-,26+,27-;/m0./s1
Verticine is a steroidal alkaloid compound extracted from the Fritillaria species of medicinal plants. Verticine was not only able to block the Nav1.7 ion channel but also preferably inhibited the Kv1.3 ion channel. It inhibits the production of inflammatory cytokines induced by LPS through blocking MAPKs and NF-κB signaling pathways. Verticine inhibited the hERG peak tail currents in a concentration dependent manner. Verticine exhibits anti-inflammatory, antitussive, antihypertensive and pain suppression properties.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2625 |
312.8 µM [IC50] | ||
Target ID: GO:0007249 |
|||
Target ID: map04010 |
|||
Target ID: CHEMBL240 |
43.7 µM [IC50] | ||
Target ID: CHEMBL4296 |
47.2 µM [IC50] | ||
Target ID: CHEMBL4633 |
142.1 µM [IC50] | ||
Target ID: CHEMBL2086 |
472.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
Verticine significantly inhibited EGF-induced MUC5AC production from NCI-H292 cells, at the highest concentration. The amounts of mucin in the cells of verticine-treated cultures were 100 ± 8%, 212 ± 10%, 217 ± 8%, 221 ± 4%, 187 ± 3% and 93 ± 4% for control, 25 ng/ml of EGF alone, EGF plus verticine 10–6 M, EGF plus verticine 2 × 10−6 M, EGF plus verticine 5 × 10–6 M and EGF plus verticine 10–5 M, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m11435
Created by
admin on Sat Dec 16 19:05:08 GMT 2023 , Edited by admin on Sat Dec 16 19:05:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
GL32ZJ6868
Created by
admin on Sat Dec 16 19:05:08 GMT 2023 , Edited by admin on Sat Dec 16 19:05:08 GMT 2023
|
PRIMARY | |||
|
90479089
Created by
admin on Sat Dec 16 19:05:08 GMT 2023 , Edited by admin on Sat Dec 16 19:05:08 GMT 2023
|
PRIMARY | |||
|
104578-56-5
Created by
admin on Sat Dec 16 19:05:08 GMT 2023 , Edited by admin on Sat Dec 16 19:05:08 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
